Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Inhibikase Therapeutics (IKT) Leases (2022 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Leases for 4 consecutive years, with $34918.0 as the latest value for Q2 2025.

  • Quarterly Leases fell 78.68% to $34918.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $34918.0 through Jun 2025, down 78.68% year-over-year, with the annual reading at $101437.0 for FY2024, 54.35% down from the prior year.
  • Leases for Q2 2025 was $34918.0 at Inhibikase Therapeutics, down from $68719.0 in the prior quarter.
  • The five-year high for Leases was $353250.0 in Q3 2022, with the low at $34918.0 in Q2 2025.
  • Average Leases over 4 years is $202497.2, with a median of $207843.5 recorded in 2023.
  • The sharpest move saw Leases decreased 29.2% in 2023, then crashed 78.68% in 2025.
  • Over 4 years, Leases stood at $328643.0 in 2022, then tumbled by 32.38% to $222227.0 in 2023, then crashed by 54.35% to $101437.0 in 2024, then crashed by 65.58% to $34918.0 in 2025.
  • According to Business Quant data, Leases over the past three periods came in at $34918.0, $68719.0, and $101437.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.